'Low-cost alternative' launched to the Aids drug hedge funder Martin Shkreli hiked 5000%
The competitor costs just $1 a pill
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.A rival company has launched a "low-cost alternative" to the Aids drug bought by a hedge fund trader who raised its price 5,000 per cent.
Martin Shkreli, the CEO of Turing Pharmaceuticals, sparked global outrage when he purchased the rights to the drug Daraprim and changed the price from £13.50 to $750 a pill.
At the time, Daraprim was the only drug on the market to contain the active ingredient pyrimethamine, and was often prescribed to patients with compromised immune systems such as those suffering from Aids and cancer.
In a press release directly referencing Turing Pharmaceuticals' Daraprim price hike, rivals Imprimis announced it would be selling a new pyrimethamine-based alternative retailing at less than $1 per pill.
Imprimis's alternative is a compound of two different drugs - pyrimethamine and leucovorin - and as such is not quite identical to Daraprim.
But the company said that the addition of leucovorin could actually help to combat the adverse impact on bone marrow which pyrimethamine can have.
The CEO of Imprimis, Mark L. Baum, said in a statement: "While we respect Turing's right to charge patients and insurance companies whatever it believes is appropriate, there may be more cost-effective compounded options for medications, such as Daraprim, for patients, physicians, insurance companies and pharmacy benefit managers to consider."
The company said it was "not the first time" a company had hiked up the price of a drug it had bought the rights to, and said it was developing a programme to offer more low-cost alternatives in the future.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments